OCR002-SP103 - Oral Immediate Release Study

NCT03846843 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cirrhosis

Interventions

DRUG: OCR-002 IR Oral Tablet
DRUG: OCR-002 Oral Solution
DRUG: OCR-002 IV Solution

Sponsor

Ocera Therapeutics, Inc.